Detalhe da pesquisa
1.
Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.
Annu Rev Immunol
; 35: 337-370, 2017 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28142321
2.
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.
Cell
; 165(3): 551-65, 2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040498
3.
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.
Nature
; 611(7934): 148-154, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171287
4.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature
; 595(7867): 432-437, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135506
5.
A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4.
Nat Immunol
; 15(12): 1134-42, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344726
6.
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.
Cell
; 165(6): 1548-1550, 2016 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27259156
7.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Nature
; 579(7798): 274-278, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103181
8.
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
J Pathol
; 263(2): 190-202, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38525811
9.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature
; 554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29443960
10.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 391(10122): 748-757, 2018 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268948
11.
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.
Nature
; 466(7309): 973-7, 2010 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20725040
12.
Brucella ß 1,2 cyclic glucan is an activator of human and mouse dendritic cells.
PLoS Pathog
; 8(11): e1002983, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23166489
13.
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Cell Rep Med
; 5(2): 101393, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280376
14.
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Cancer Cell
; 42(3): 429-443.e4, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38366589
15.
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
Clin Cancer Res
; 28(18): 4083-4091, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877091
16.
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
JAMA Oncol
; 8(2): 275-280, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940781
17.
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Cancer Cell
; 40(3): 289-300.e4, 2022 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216676
18.
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Eur Urol
; 82(2): 212-222, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577646
19.
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
Cancer Cell
; 40(9): 1027-1043.e9, 2022 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099881
20.
Molecular determinants of response to PD-L1 blockade across tumor types.
Nat Commun
; 12(1): 3969, 2021 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172722